BRYAN ISHMAEL: Open Payments
NPI 1730924085 · KERRVILLE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$898 in 49 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $50 · 2025 $898
Food & beverage: $898
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 13 | $210 |
| ABBVIE INC. | 12 | $197 |
| Madrigal Pharmaceuticals | 5 | $97 |
| PFIZER INC. | 4 | $80 |
| Ipsen Biopharmaceuticals, Inc | 3 | $72 |
| Gilead Sciences, Inc. | 2 | $42 |
| GENZYME CORPORATION | 2 | $42 |
| Aimmune Therapeutics, Inc. | 2 | $39 |
| Ardelyx, Inc. | 2 | $34 |
| Celltrion USA Inc. | 1 | $25 |
Products named: TREMFYA, MAVYRET, REZDIFFRA, IQIRVO, XELJANZ, RINVOQ, DUPIXENT, ZENPEP.
Industry payments across TX — which companies pay providers there.
